{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:27:14Z","timestamp":1787016434978,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1124\/jpet.110.175075","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T22:39:27Z","timestamp":1302820767000},"page":"302-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The Ligands of Estrogen Receptor \u03b1 Regulate Cytochrome P4502C9 (CYP2C9) Expression"],"prefix":"10.1016","volume":"338","author":[{"given":"Jessica","family":"Mwinyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isa","family":"Cavaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begum","family":"Yurdakok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souren","family":"Mkrtchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Ingelman-Sundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.175075_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.abb.2004.03.032","article-title":"Role of hepatocyte nuclear factor 3\u03b3 in the expression of human CYP2C genes","volume":"426","author":"Bort","year":"2004","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/jpet.110.175075_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1179\/joc.2006.18.4.421","article-title":"Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients","volume":"18","author":"Boruban","year":"2006","journal-title":"J Chemother"},{"key":"10.1124\/jpet.110.175075_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1124\/jpet.103.058818","article-title":"Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor","volume":"308","author":"Chen","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.175075_bib4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1124\/jpet.105.087072","article-title":"The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4\u03b1 to synergistically activate the human CYP2C9 promoter","volume":"314","author":"Chen","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.175075_bib5","first-page":"148","article-title":"Role of cytochrome P450 in estradiol metabolism in vitro","volume":"22","author":"Cheng","year":"2001","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/jpet.110.175075_bib6","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1210\/endo.138.11.5496","article-title":"Tissue distribution and quantitative analysis of estrogen receptor-\u03b1 (ER\u03b1) and estrogen receptor-\u03b2 (ER\u03b2) messenger ribonucleic acid in the wild-type and ER\u03b1-knockout mouse","volume":"138","author":"Couse","year":"1997","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.110.175075_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/nar\/11.5.1475","article-title":"Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei","volume":"11","author":"Dignam","year":"1983","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/jpet.110.175075_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/GIM.0b013e318163c35f","article-title":"Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin","volume":"10","author":"Flockhart","year":"2008","journal-title":"Genet Med"},{"key":"10.1124\/jpet.110.175075_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","article-title":"Clinical relevance of genetic polymorphisms in the human CYP2C subfamily","volume":"52","author":"Goldstein","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.110.175075_bib10","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1124\/dmd.107.016568","article-title":"Human CYP2A6 is induced by estrogen via estrogen receptor","volume":"35","author":"Higashi","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.110.175075_bib11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1124\/dmd.106.009365","article-title":"Involvement of hepatocyte nuclear factor 4\u03b1 in the different expression level between CYP2C9 and CYP2C19 in the human liver","volume":"34","author":"Kawashima","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.110.175075_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.110.175075_bib13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1034\/j.1600-0773.2003.t01-1-930202_93_2.x","article-title":"A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes","volume":"93","author":"Laine","year":"2003","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/jpet.110.175075_bib14","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1124\/mol.106.025403","article-title":"Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4\u03b1 requires coactivators peroxisomal proliferator activated receptor-\u03b3 coactivator 1\u03b1 and steroid receptor coactivator 1","volume":"70","author":"Mart\u00ednez-Jim\u00e9nez","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.110.175075_bib15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.110.175075_bib16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1124\/mol.110.065540","article-title":"Regulation of CYP2C19 expression by estrogen receptor \u03b1: implications for estrogen-dependent inhibition of drug metabolism","volume":"78","author":"Mwinyi","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.110.175075_bib17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.lfs.2010.02.021","article-title":"The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression","volume":"86","author":"Mwinyi","year":"2010","journal-title":"Life Sci"},{"key":"10.1124\/jpet.110.175075_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1124\/dmd.109.029405","article-title":"New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4","volume":"38","author":"Mwinyi","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.110.175075_bib19","first-page":"5885","article-title":"A position-dependent silencer plays a major role in repressing \u03b1-fetoprotein expression in human hepatoma","volume":"11","author":"Nakabayashi","year":"1991","journal-title":"Mol Cell Biol"},{"key":"10.1124\/jpet.110.175075_bib20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.yexcr.2005.12.023","article-title":"Peroxisome proliferator-activated receptor \u03b3 regulates expression of signal transducer and activator of transcription 5A","volume":"312","author":"Olsen","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1124\/jpet.110.175075_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.clpt.2003.09.015","article-title":"CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy","volume":"75","author":"Peyvandi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.110.175075_bib22","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/dmd.32.5.484","article-title":"The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype","volume":"32","author":"Sandberg","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.110.175075_bib23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.0306-5251.2001.01460.x","article-title":"Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population","volume":"52","author":"Scordo","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.110.175075_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","article-title":"Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs","volume":"47","author":"Urquhart","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.110.175075_bib25","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1210\/me.2003-0446","article-title":"Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effects of ER\u03b1 and ER\u03b2","volume":"18","author":"van de Stolpe","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1124\/jpet.110.175075_bib26","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1345\/aph.1M382","article-title":"Probable drug interaction between warfarin and hormonal contraceptives","volume":"43","author":"Zingone","year":"2009","journal-title":"Ann Pharmacother"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524464513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.175075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T21:32:16Z","timestamp":1740000736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524464513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0022356524464513"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.175075","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.10514956.11362055","asserted-by":"object"}]},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Ligands of Estrogen Receptor \u03b1 Regulate Cytochrome P4502C9 (CYP2C9) Expression","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.175075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}